The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation
Abstract
Importance: Dabigatran and rivaroxaban are non-vitamin K oral anticoagulants approved for stroke prevention in patients with nonvalvular atrial fibrillation (AF). There are no randomized head-to-head comparisons of these drugs for stroke, bleeding, or mortality outcomes. Objective: To compare risks of thromboembolic stroke, intracranial hemorrhage (ICH), major extracranial bleeding including major gastrointestinal bleeding, and mortality in patients with nonvalvular AF who initiated dabigatran or rivaroxaban treatment for stroke prevention. Design, Setting, and Participants: Retrospective new-user cohort study of 118 891 patients with nonvalvular AF who were 65 years or older, enrolled in fee-for-service Medicare, and who initiated treatment with dabigatran or rivaroxaban from November 4, 2011, through June 30, 2014. Differences in baseline characteristics were adjusted using stabilized inverse probability of treatment weights based on propensity scores. The data analysis was performed from May 7, 2015, through June 30, 2016. Exposures: Dabigatran, 150 mg, twice daily; rivaroxaban, 20 mg, once daily. Main Outcomes and Measures: Adjusted hazard ratios (HRs) for the primary outcomes of thromboembolic stroke, ICH, major extracranial bleeding including major gastrointestinal bleeding, and mortality, with dabigatran as reference. Adjusted incidence rate differences (AIRDs) were also estimated. Results: A total of 52 240 dabigatran-treated and 66 651 rivaroxaban-treated patients (47% female) contributed 15 524 and 20 199 person-years of on-treatment follow-up, respectively, during which 2537 primary outcome events occurred. Rivaroxaban use was associated with a statistically nonsignificant reduction in thromboembolic stroke (HR, 0.81; 95% CI, 0.65-1.01; P = .07; AIRD = 1.8 fewer cases/1000 person-years), statistically significant increases in ICH (HR, 1.65; 95% CI, 1.20-2.26; P = .002; AIRD = 2.3 excess cases/1000 person-years) and major extracranial bleeding (HR, 1.48; 95% CI, 1.32-1.67; P < .001; AIRD = 13.0 excess cases/1000 person-years), including major gastrointestinal bleeding (HR, 1.40; 95% CI, 1.23-1.59; P < .001; AIRD = 9.4 excess cases/1000 person-years), and with a statistically nonsignificant increase in mortality (HR, 1.15; 95% CI, 1.00-1.32; P = .051; AIRD = 3.1 excess cases/1000 person-years). In patients 75 years or older or with CHADS2 score greater than 2, rivaroxaban use was associated with significantly increased mortality compared with dabigatran use. The excess rate of ICH with rivaroxaban use exceeded its reduced rate of thromboembolic stroke. Conclusions and Relevance: Treatment with rivaroxaban 20 mg once daily was associated with statistically significant increases in ICH and major extracranial bleeding, including major gastrointestinal bleeding, compared with dabigatran 150 mg twice daily.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Austin, P. C. (2011) · Multivariate Behavioral Research · doi:10.1080/00273171.2011.568786 · Cited by 12,242
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Lip, G. Y. H., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. G. M. (2010) · Chest · doi:10.1378/chest.09-1584 · Cited by 6,879
Go, A. S., Hylek, E. M., Phillips, K. A., Chang, Y., Henault, L. E., Selby, J. V., & Singer, D. E. (2001) · JAMA · doi:10.1001/jama.285.18.2370 · Cited by 6,205
Marginal Structural Models and Causal Inference in Epidemiology
Robins, J. M., Hernán, M. Á., & Brumback, B. (2000) · Epidemiology · doi:10.1097/00001648-200009000-00011 · Cited by 5,581
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J. G. M., & Lip, G. Y. H. (2010) · Chest · doi:10.1378/chest.10-0134 · Cited by 4,505
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Benjamin, E. J. (1994) · JAMA · doi:10.1001/jama.1994.03510350050036 · Cited by 2,613
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646
Hylek, E. M., Evans-Molina, C., Shea, C., Henault, L. E., & Regan, S. (2007) · Circulation · doi:10.1161/circulationaha.106.653048 · Cited by 1,061
Rosenbaum, P. R. (1987) · Journal of the American Statistical Association · doi:10.1080/01621459.1987.10478441 · Cited by 997
Harder, V. S., Stuart, E. A., & Anthony, J. C. (2010) · Psychological Methods · doi:10.1037/a0019623 · Cited by 802
Xu, S., Ross, C., Raebel, M. A., Shetterly, S., Blanchette, C., & Smith, D. (2010) · Value in Health · doi:10.1111/j.1524-4733.2009.00671.x · Cited by 796
Kokotailo, R. A., & Hill, M. D. (2005) · Stroke · doi:10.1161/01.str.0000174293.17959.a1 · Cited by 709
Validating Administrative Data in Stroke Research
Tirschwell, D. L., & Longstreth, W. T. (2002) · Stroke · doi:10.1161/01.str.0000032240.28636.bd · Cited by 658
Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding
Mamdani, M., Sykora, K., Li, P., Normand, S.-L. T., Streiner, D. L., Austin, P. C., Rochon, P. A., & Anderson, G. M. (2005) · BMJ · doi:10.1136/bmj.330.7497.960 · Cited by 646
Graham, D. J., Reichman, M. E., Wernecke, M., Zhang, R., Southworth, M. R., Levenson, M., Sheu, T.-C., Mott, K., Goulding, M. R., Houstoun, M., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.012061 · Cited by 644
Self-citationNational trends in ambulatory oral anticoagulant use
Barnes, G. D., Lucas, E., Alexander, G. C., & Goldberger, Z. D. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.05.044 · Cited by 598
Kiyota, Y., Schneeweiss, S., Glynn, R. J., Cannuscio, C. C., Avorn, J., & Solomon, D. H. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.02.013 · Cited by 531
Austin, P. C., Daly, P. A., & Tu, J. V. (2002) · American Heart Journal · doi:10.1067/mhj.2002.123839 · Cited by 525
An automated database case definition for serious bleeding related to oral anticoagulant use
Cunningham, A., Stein, C. M., Chung, C. P., Daugherty, J. R., Smalley, W. E., & Ray, W. A. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2109 · Cited by 359
Dabigatran and Postmarketing Reports of Bleeding
Southworth, M. R., Reichman, M. E., & Unger, E. F. (2013) · New England Journal of Medicine · doi:10.1056/nejmp1302834 · Cited by 353
Self-citationAbraham, N. S., Singh, S., Alexander, G. C., Heien, H., Haas, L. R., Crown, W., & Shah, N. D. (2015) · BMJ · doi:10.1136/bmj.h1857 · Cited by 347
Lip, G. Y. H., Larsen, T. B., Skjøth, F., & Rasmussen, L. H. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.019 · Cited by 288
Risk of Bleeding With Dabigatran in Atrial Fibrillation
Hernandez, I., Baik, S. H., Piñera, A., & Zhang, Y. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.5398 · Cited by 264
Warfarin Anticoagulation and Outcomes in Patients With Atrial Fibrillation
Reynolds, M. W., Fahrbach, K., Hauch, O., Wygant, G., Estok, R., Cella, C., & Nalysnyk, L. (2004) · Chest · doi:10.1378/chest.126.6.1938 · Cited by 262
Aguilar, M. I., & Hart, R. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001927.pub2 · Cited by 252
Petersen, L. A., Wright, S., Normand, S.-L. T., & Daley, J. (1999) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.1999.10198.x · Cited by 233
6. A Diagnostic Routine for the Detection of Consequential Heterogeneity of Causal Effects
Morgan, S. L., & Todd, J. J. (2008) · Sociological Methodology · doi:10.1111/j.1467-9531.2008.00204.x · Cited by 207
Roumie, C. L., Mitchel, E., Gideon, P. S., Varas‐Lorenzo, C., Castellsague, J., & Griffin, M. R. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1518 · Cited by 192
Coding accuracy of hospital discharge data for elderly survivors of myocardial infarction.
Levy, A., Tamblyn, R. M., FITCHETT, D. H., McLeod, P. J., & Hanley, J. A. (1999) · PubMed · Cited by 191
Wahl, P. M., Rodgers, K., Schneeweiss, S., Gage, B. F., Butler, J., Wilmer, C., Nash, M., Esper, G., Gitlin, N., Osborn, N., et al. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1924 · Cited by 174
Chang, H., Zhou, M., Tang, W., Alexander, G. C., & Singh, S. (2015) · BMJ · doi:10.1136/bmj.h1585 · Cited by 152
Comparative Efficacy and Safety of New Oral Anticoagulants in Patients With Atrial Fibrillation
Schneeweiß, S., Gagne, J. J., Patrick, A. R., Choudhry, N. K., & Avorn, J. (2012) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.112.965988 · Cited by 146
Hill, M. E., & Rosenwaike, I. (2001) · PubMed · Cited by 145
Gorst‐Rasmussen, A., Lip, G. Y. H., & Larsen, T. B. (2016) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4034 · Cited by 85
An algorithm to identify incident myocardial infarction using Medicaid data
Choma, N. N., Griffin, M. R., Huang, R. L., Mitchel, E. F., Kaltenbach, L. A., Gideon, P. S., Stratton, S. M., & Roumie, C. L. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1821 · Cited by 46
Wang, S. V., Franklin, J. M., Glynn, R. J., Schneeweiß, S., Eddings, W., & Gagne, J. J. (2016) · BMJ · doi:10.1136/bmj.i2607 · Cited by 35
Cited by
January, C. T., Wann, L. S., Calkins, H., Chen, L. Y., Cigarroa, J. E., Cleveland, J. C., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., Furie, K. L., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000665 · Cited by 2,744
January, C. T., Wann, L. S., Calkins, H., Chen, L. Y., Cigarroa, J. E., Cleveland, J. C., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., Furie, K. L., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.011 · Cited by 2,205
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab065 · Cited by 1,132
Antithrombotic Therapy for Atrial Fibrillation
Lip, G. Y. H., Banerjee, A., Boriani, G., Chiang, C. E., Fargo, R., Freedman, B., Lane, D. A., Ruff, C. T., Turakhia, M., Werring, D., et al. (2018) · Chest · doi:10.1016/j.chest.2018.07.040 · Cited by 939
Langan, S. M., Schmidt, S. A., Wing, K., Ehrenstein, V., Nicholls, S. G., Filion, K. B., Klungel, O., Petersen, I., Sorensen, H. T., Dixon, W. G., et al. (2018) · BMJ · doi:10.1136/bmj.k3532 · Cited by 550
Metadata
- Authors
- Graham, D. J., Reichman, M. E., Wernecke, M., Hsueh, Y.-H., Izem, R., Southworth, M. R., Wei, Y., Liao, J., Goulding, M. R., Mott, K., Chillarige, Y., MaCurdy, T. E., Worrall, C., & Kelman, J. A.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2016-11-01
- Volume
- 176
- Issue
- 11
- Pages
- 1662
- ISSN
- 2168-6106 (ISSN-L)
- OpenAlex
- W2529460814
- Cited by
- 312
- References
- 42
- FWCI
- 43.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.